OP LIPOSOMAL DOXORUBICIN / BEVACIZUMAB

Types: ONCOLOGY TREATMENT

Synonyms: LIPOSOMAL, DOXORUBICIN, DOXIL, DOC, BREAST, OVARIAN, GYNECOLOGIC, AVAST, BEVA

Cycles 1 to 3	2	Repeat 3	timos	Cycle length: 28 days			
Day 1	,	nepearo	unies	Cycle length. 20 days	Perform every 1 day x1		
	ppoir	ntment Requests			, ,		
		INFUSION APPOINTM Interval:	Occurrences:				
13	abs	Interval	Occurrences.				
	abs		TAROLIC PANEL				
		Interval:	Occurrences:				
				A1			
		☑ CBC WITH PLATELET Interval	_	AL			
		Interval:	Occurrences:				
		☑ MAGNESIUM LEVEL	_				
		Interval:	Occurrences:				
		URINALYSIS, AUTOMATED WITH ☑ MICROSCOPY					
		Interval:	Occurrences:				
		□ CANCER ANTIGEN 125					
		Interval:	Occurrences:				
0	Outpa	tient Electrolyte Replaceme					
		TREATMENT CONDIT					
		Comments:	Occurrences: Potassium (Normal range 3.5 to 5.0mEq/L)				
			o Protocol a	pplies for SCr less than 1.5. C	Otherwise, contact		
			MD/NP o Protocol a	pplies only to same day lab va	alue		
			o Serum po	tassium less than 3.0mEq/L, g			
			PO and contact M		40mFa / CL		
				tassium 3.0 to 3.2mEq/L, give tassium 3.3 to 3.4mEq/L, give			
			do not give potassium				
			replacement o If patient r	neets criteria, order SmartSet	called "Outpatient		
			ement"	caned Outpatient			
			rolyte replacement order as P	er protocol: cosign			
			required				
		TREATMENT CONDITIONS 40					
		Interval:	Occurrences:				
		Comments:		nal range 1.6 to 2.6mEq/L) pplies for SCr less than 1.5. C	Otherwise, contact		
			MD/NP	• •			
				pplies only to same day lab va gnesium less than 1.0mEq/L,			
			sulfate IV and con		give 2 grain magnesium		
				agnesium 1.0 to 1.2mEq/L, giv	re 2 gram magnesium		
			sulfate IV o Serum Ma	agnesium 1.3 to 1.5mEq/L, giv	e 1 gram magnesium		
			sulfate IV				
			o Serum Ma	anesium 1.6 mEa/L or areate	r. do not aive		

magnesium replacement

o If patient meets criteria, order SmartSet called "Outpatient

Electrolyte Replacement"

o Sign electrolyte replacement order as Per protocol: cosign

required

Nursing Orders

TREATMENT CONDITIONS

Interval: -- Occurrences: --

Comments: Do NOT administer within 28 days of surgery/procedure and until the

surgical wound is fully healed or within 14 days of port placement.

Provider Communication

ONC PROVIDER COMMUNICATION

Interval: -- Occurrences: --

Comments: Verify Ejection Fraction prior to Cycle 1. Ejection Fraction: ***% on ***

(date).

If patient has not had a recent MUGA or ECHO, order one via order entry. A baseline cardiac evaluation with a MUGA scan or an ECHO is recommended, especially in patients with risk factors for increased cardiac toxicity. Repeated MUGA or ECHO determinations of LVEF should be performed, particularly with higher, cumulative anthracycline

doses.

Nursing Orders

TREATMENT CONDITIONS 5

Interval: -- Occurrences: --

Comments: HOLD and notify provider if PROTEIN 2+ is detected in UA.

Nursing Orders

TREATMENT CONDITIONS 7

Interval: -- Occurrences: --

Comments: HOLD and notify provider if ANC LESS than 1000; Platelets LESS than

100,000.

Line Flush

dextrose 5% flush syringe 20 mL

Dose: 20 mL Route: intravenous PRN

Start: S Instructions:

Administer ONLY for Liposomal Doxorubicin.

sodium chloride 0.9 % flush 20 mL

Dose: 20 mL Route: intravenous PRN

Start: S Instructions:

Do NOT administer with Liposomal

Doxorubicin.

Nursing Orders

dextrose 5% infusion 250 mL

Dose: 250 mL Route: intravenous once @ 30 mL/hr for 1 dose

Start: S Instructions:

To keep vein open for Liposomal Doxorubicin.

sodium chloride 0.9 % infusion 250 mL

Dose: 250 mL Route: intravenous once @ 30 mL/hr for 1 dose

Start: S Instructions:

To keep vein open. Do NOT administer with

Dro M	Liposomal Doxorubicin.										
Pre-IVI	Medications ondansetron (ZOFRAN) 4 mg/2 mL injection 8										
	mg										
	Dose: 8 mg Start: S	Route: intravenous End: S 11:15 AM	once for 1 dos	se							
	O ondansetron (ZOFRAN) tablet 16 mg										
	Dose: 16 mg Start: S	Route: oral	once for 1 dos	se							
	 ondansetron (ZOFRAN) 4 mg/2 mL 16 mg in dextrose 5% 50 mL IVPB 										
	Dose: 16 mg Start: S	Route: intravenous End: S 11:00 AM	once over 15 Minutes for 1 dose								
	Ingredients:	Name ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION	Type Medications	Dose 16 mg	Selected Main Ingredient	Adds Vol. No					
		DEXTROSE 5 % IN WATER (D5W) INTRAVENOUS SOLUTION	Base	50 mL	Always	Yes					
Pre-Medications											
	☑ acetaminophen (TYLENOL) tablet 650 mg										
	Dose: 650 mg Route: oral once for 1 dose Start: S Instructions: Pre-med for Avastin										
	☑ diphenhydrAMINE (BENADRYL) tablet 25 mg										
	Dose: 25 mg Start: S Instructions: Pre-med for Avastin	Route: oral	once for 1 dos	Se							
	□ dexamethasone (DECADRON) injection 10 mg										
	Dose: 10 mg Start: S Instructions: Pre-med for Avastin	Route: intravenous	once for 1 dos	se							
Suppo	ortive Care										
	○ LORAZepam (ATIVAN)	injection 1 mg									
	Dose: 1 mg Start: S	Route: intravenous	once PRN								
	○ LORAZepam (ATIVAN) tablet 1 mg										
	Dose: 1 mg Start: S	Route: oral	once PRN								
Antien	Antiemetics										
	opromethazine (PHENERGAN) injection 12.5 mg										
	Dose: 12.5 mg Start: S	Route: injection	once PRN								
Chem	otherapy	-1 (DOVII) 40 / C :									
	DUXUrubicin liposoma	al (DOXIL) 40 mg/m2 in									

dextrose 5% 250 mL chemo IVPB

once over 1 Hours for 1 dose Dose: 40 mg/m2 Route: intravenous

Offset: 30 Minutes

Instructions:

DRUG IS AN IRRITANT. Initial infusion. infused at 1 mg/min, but no faster than 1 hour to prevent infusion related reactions. Monitor vital signs 15 minutes, 30 minutes, and one hour into infusion, then hourly for remainder of initial infusion. Stay with patient for the first 15 minutes of the initial infusion. If patient tolerated initial infusion, subsequent infusions

to be given over 1 hour.

Ingredients: **Type** Dose Selected Adds Vol. Name

DOXORUBICIN. Medications 40 mg/m2 Main Yes PEGYLATED Ingredient

LIPOSOMAL 2 MG/ML

INTRAVENOUS SUSPENSION

DEXTROSE 5 % IN QS Base 250 mL Yes Yes

WATER (D5W) **INTRAVENOUS** SOLUTION

Chemotherapy

bevacizumab (AVASTIN) 10 mg/kg in sodium chloride 0.9 % 100 mL chemo IVPB

Dose: 10 mg/kg Route: intravenous once over 30 Minutes for 1 dose

Start: S End: S 12:15 PM

Ingredients: Dose Selected Adds Vol. Name Type

> BEVACIZUMAB 25 Medications 10 mg/kg Main Yes Ingredient

MG/ML

INTRAVENOUS SOLUTION

SODIUM **QS** Base 100 mL Yes Yes

CHLORIDE 0.9 % **INTRAVENOUS** SOLUTION

Hematology & Oncology Hypersensitivity Reaction Standing Order

ONC NURSING COMMUNICATION 82

Interval: --Occurrences: --

Comments: Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms

only – itching, flushing, periorbital edema, rash, or runny nose)

1. Stop the infusion.

2. Place the patient on continuous monitoring.

3. Obtain vital signs.

4. Administer Normal Saline at 50 mL per hour using a new bag and new

intravenous tubing.

5. If greater than or equal to 30 minutes since the last dose of

Diphenhydramine, administer Diphenhydramine 25 mg intravenous

once. 6. If less than 30 minutes since the last dose of Diphenhydramine,

administer Fexofenadine 180 mg orally and Famotidine 20 mg

intravenous once.

7. Notify the treating physician.

8. If no improvement after 15 minutes, advance level of care to Grade 2

(Moderate) or Grade 3 (Severe).

9. Assess vital signs every 15 minutes until resolution of symptoms or

otherwise ordered by covering physician.

ONC NURSING COMMUNICATION 4

Interval: --

Occurrences: --

Comments:

Grade 2 – MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms – shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)

1. Stop the infusion.

2. Notify the CERT team and treating physician immediately.

3. Place the patient on continuous monitoring.

4. Obtain vital signs.

5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.

6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.

7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Fexofenadine 180 mg orally and Famotidine 20 mg intravenous once.

8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).

9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

ONC NURSING COMMUNICATION 83

Interval: --

Occurrences: --

Comments:

Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)

1. Stop the infusion.

2. Notify the CERT team and treating physician immediately.

3. Place the patient on continuous monitoring.

4. Obtain vital signs.

5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to

maintain O2 saturation of greater than or equal to 92%.

7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.

8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.

9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.

10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

diphenhydrAMINE (BENADRYL) injection 25

mg

Dose: 25 mg

Route: intravenous

PRN

Start: S

fexofenadine (ALLEGRA) tablet 180 mg

Dose: 180 mg

Route: oral

PRN

Start: S

famotidine (PEPCID) 20 mg/2 mL injection 20

mq

Dose: 20 mg

Route: intravenous

PRN

Start: S

hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg Dose: 100 mg Route: intravenous **PRN** dexamethasone (DECADRON) injection 4 mg Dose: 4 ma **PRN** Route: intravenous Start: S epINEPHrine (ADRENALIN) 1 mg/10 mL ADULT injection syringe 0.3 mg Dose: 0.3 mg **PRN** Route: subcutaneous Start: S Discharge Nursing Orders **ONC NURSING COMMUNICATION 76** Interval: --Occurrences: --Comments: Discontinue IV. Discharge Nursing Orders Dose: 20 mL Route: intravenous PRN ☑ HEParin, porcine (PF) injection 500 Units Dose: 500 Units Route: intra-catheter once PRN Start: S Instructions: Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance. **Day 15** Perform every 1 day x1 **Appointment Requests INFUSION APPOINTMENT REQUEST** Interval: --Occurrences: --Labs ☐ COMPREHENSIVE METABOLIC PANEL Interval: --Occurrences: -- □ CBC WITH PLATELET AND DIFFERENTIAL Interval: --Occurrences: --MAGNESIUM LEVEL Interval: --Occurrences: --**URINALYSIS. AUTOMATED WITH MICROSCOPY** Interval: --Occurrences: --**□ CANCER ANTIGEN 125** Interval: --Occurrences: --Outpatient Electrolyte Replacement Protocol **TREATMENT CONDITIONS 39** Interval: --Occurrences: --Comments: Potassium (Normal range 3.5 to 5.0mEq/L) Protocol applies for SCr less than 1.5. Otherwise, contact MD/NP Protocol applies only to same day lab value. 0 Serum potassium less than 3.0mEg/L, give 40mEg KCL IV or PO and contact MD/NP

Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO

- o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO
- o Serum potassium 3.5 mEq/L or greater, do not give potassium

replacement

o If patient meets criteria, order SmartSet called "Outpatient

Electrolyte Replacement"

o Sign electrolyte replacement order as Per protocol: cosign

required

TREATMENT CONDITIONS 40

Interval: -- Occurrences: --

Comments: Magnesium (Normal range 1.6 to 2.6mEq/L)

o Protocol applies for SCr less than 1.5. Otherwise, contact

MD/NP

o Protocol applies only to same day lab value.

o Serum Magnesium less than 1.0mEq/L, give 2 gram magnesium

sulfate IV and contact MD/NP

Serum Magnesium 1.0 to 1.2mEq/L, give 2 gram magnesium

sulfate IV

o Serum Magnesium 1.3 to 1.5mEq/L, give 1 gram magnesium

sulfate IV

o Serum Magnesium 1.6 mEq/L or greater, do not give

magnesium replacement

o If patient meets criteria, order SmartSet called "Outpatient

Electrolyte Replacement"

o Sign electrolyte replacement order as Per protocol: cosign

required

Nursing Orders

TREATMENT CONDITIONS

Interval: -- Occurrences: --

Comments: Do NOT administer within 28 days of surgery/procedure and until the

surgical wound is fully healed or within 14 days of port placement.

Nursing Orders

TREATMENT CONDITIONS 5

Interval: -- Occurrences: --

Comments: HOLD and notify provider if PROTEIN 2+ is detected in UA.

Nursing Orders

TREATMENT CONDITIONS 7

Interval: -- Occurrences: --

Comments: HOLD and notify provider if ANC LESS than 1000; Platelets LESS than

100,000.

Line Flush

sodium chloride 0.9 % flush 20 mL

Dose: 20 mL Route: intravenous PRN

Start: S

Nursing Orders

sodium chloride 0.9 % infusion 250 mL

Dose: 250 mL Route: intravenous once @ 30 mL/hr for 1 dose

Start: S Instructions:

To keep vein open.

Pre-Medications

Dose: 650 mg Route: oral once for 1 dose

Start: S

Instructions:

Pre-med for Avastin

diphenhydrAMINE (BENADRYL) tablet 25 mg

Dose: 25 mg

Route: oral

once for 1 dose

Start: S Instructions:

Pre-med for Avastin

☐ dexamethasone (DECADRON) injection 10 mg

Dose: 10 mg

Route: intravenous

once for 1 dose

Start: S Instructions:

Start: S

Pre-med for Avastin

Chemotherapy

bevacizumab (AVASTIN) 10 mg/kg in sodium

chloride 0.9 % 100 mL chemo IVPB

Dose: 10 mg/kg

Route: intravenous

once over 30 Minutes for 1 dose

End: S 12:15 PM

Ingredients: Name

NameTypeDoseSelectedAdds Vol.BEVACIZUMAB 25Medications10 mg/kgMainYesMG/MLIngredient

INTRAVENOUS

SOLUTION

SODIUM QS Base 100 mL Yes Yes

CHLORIDE 0.9 % INTRAVENOUS SOLUTION

Hematology & Oncology Hypersensitivity Reaction Standing Order

ONC NURSING COMMUNICATION 82

Interval: -- Occurrences: --

Comments: Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms

only – itching, flushing, periorbital edema, rash, or runny nose)

1. Stop the infusion.

2. Place the patient on continuous monitoring.

3. Obtain vital signs.

4. Administer Normal Saline at 50 mL per hour using a new bag and new

intravenous tubing.

5. If greater than or equal to 30 minutes since the last dose of

Diphenhydramine, administer Diphenhydramine 25 mg intravenous

once.

6. If less than 30 minutes since the last dose of Diphenhydramine,

administer Fexofenadine 180 mg orally and Famotidine 20 mg

intravenous once.

7. Notify the treating physician.

8. If no improvement after 15 minutes, advance level of care to Grade 2

(Moderate) or Grade 3 (Severe).

9. Assess vital signs every 15 minutes until resolution of symptoms or

otherwise ordered by covering physician.

ONC NURSING COMMUNICATION 4

Interval: -- Occurrences: --

Comments: Grade 2 – MODERATE Symptoms (cardiovascular, respiratory, or

gastrointestinal symptoms – shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or

back pain)

1. Stop the infusion.

2. Notify the CERT team and treating physician immediately.

3. Place the patient on continuous monitoring.

4. Obtain vital signs.

- 5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
- 6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
- 7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Fexofenadine 180 mg orally and Famotidine 20 mg intravenous once.
- 8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
- 9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

ONC NURSING COMMUNICATION 83

Interval: --

Occurrences: --

Comments: Gra

Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)

- 1. Stop the infusion.
- 2. Notify the CERT team and treating physician immediately.
- 3. Place the patient on continuous monitoring.
- 4. Obtain vital signs.
- 5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.

 6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to
- maintain O2 saturation of greater than or equal to 92%.
- 7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
- 8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
- 9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
- 10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

diphenhydrAMINE (BENADRYL) injection 25

mg

Dose: 25 mg

Route: intravenous

PRN

PRN

Start: S

fexofenadine (ALLEGRA) tablet 180 mg

Dose: 180 mg Route: oral

Start: S

famotidine (PEPCID) 20 mg/2 mL injection 20

ma

Dose: 20 mg

Route: intravenous

PRN

Start: S

hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg

Dose: 100 mg Route: intravenous PRN

dexamethasone (DECADRON) injection 4 mg

Dose: 4 mg Route: intravenous PRN

Start: S

epINEPHrine (ADRENALIN) 1 mg/10 mL ADULT

injection syringe 0.3 mg

Dose: 0.3 mg Route: subcutaneous PRN

Start: S

Discharge Nursing Orders

ONC NURSING COMMUNICATION 76

Interval: -- Occurrences: -- Comments: Discontinue IV.

Discharge Nursing Orders

✓ sodium chloride 0.9 % flush 20 mL

Dose: 20 mL Route: intravenous PRN

☑ HEParin, porcine (PF) injection 500 Units

Dose: 500 Units Route: intra-catheter once PRN

Start: S Instructions:

Concentration: 100 units/mL. Heparin flush for

Implanted Vascular Access Device

maintenance.